Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation: a preliminary report

Transplant Proc. 2012 Jan;44(1):175-8. doi: 10.1016/j.transproceed.2011.11.026.


Object: This study aims to investigate the impact of anti-CD25 monoclonal antibody (basiliximab) on peripheral blood regulatory T cells (Treg) and their subsets in recipients early after renal transplantation.

Methods: Ten renal transplant recipients from November 2009 to February 2011 were divided into an induction therapy and a no-induction therapy group, mainly based on their will to accept basiliximab induction. Peripheral blood samples were collected at 2 hours before as well as 1 and 2 weeks after transplantation. Flow cytometry was used to analyze the proportion of regulatory T cells and their subsets.

Results: Compared with the no-induction therapy group, the proportions of both CD25(high) T cell and CD25(high) Foxp3(+) double marked T cells were significantly decreased among in the basiliximab induction group remaining at low at 2 weeks. The subsets of activated Treg and cytokine-secreting Treg were also temporarily downregulated at 1 week after transplantation using basiliximab induction. However, the inhibitory transcriptional factor Foxp3 was not significantly affected by the induction therapy.

Conclusions: Anti-CD25 monoclonal antibody downregulated the proportion of regulatory T cell and its activated subsets in peripheral blood in the early stage after renal transplantation while the inhibitory function may still be spared.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Case-Control Studies
  • China
  • Cytokines / blood
  • Female
  • Flow Cytometry
  • Forkhead Transcription Factors / blood
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-2 Receptor alpha Subunit / blood
  • Kidney Transplantation / immunology*
  • Lymphocyte Activation / drug effects*
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / therapeutic use*
  • T-Lymphocytes, Regulatory / drug effects*
  • T-Lymphocytes, Regulatory / immunology
  • Time Factors
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Cytokines
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • IL2RA protein, human
  • Immunosuppressive Agents
  • Interleukin-2 Receptor alpha Subunit
  • Recombinant Fusion Proteins
  • Basiliximab